Differential response to risperidone in schizophrenia patients by KCNH2Genotype and drug metabolizer status

American Journal of Psychiatry

Volumn 173, Issue 1, 2016, Pages 53-59

  Heide, Juliane ^a   Zhang, Fengyu ^a   Bigos, Kristin L ^a   Mann, Stefan A ^a   Carr, Vaughan J ^a   Weickert, Cynthia Shannon ^a   Green, Melissa J ^a   Weinberger, Daniel R ^a   Vandenberg, Jamie I ^a  

^a VICTOR CHANG CARDIAC RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; ISOPROTEIN; OLANZAPINE; PALIPERIDONE; POTASSIUM CHANNEL; POTASSIUM CHANNEL KV11 1; POTASSIUM CHANNEL KV11 1 1A ISOFORM; POTASSIUM CHANNEL KV11 1 3 1 ISOFORM; RISPERIDONE; UNCLASSIFIED DRUG; ERG1 POTASSIUM CHANNEL; NEUROLEPTIC AGENT; POTASSIUM CHANNEL HERG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESPONSE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; IC50; KCNH2 GENE; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; ADULT; ALTERNATIVE RNA SPLICING; GENETICS; MALE; METABOLISM; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ALTERNATIVE SPLICING; ANTIPSYCHOTIC AGENTS; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; GENOTYPE; HUMANS; MALE; PROTEIN ISOFORMS; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84954290782     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2015.14050653     Document Type: Article

References (27)

1. World Health Organization: Mental Health: Schizophrenia. http://www.who.int/mental-health/management/schizophrenia/en/
2. Kongsamut S, Kang J, Chen XL, et al: A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol 2002;450:37-41
3. Weinberger DR, Harrison PJ: Schizophrenia, 3rd ed. Oxford, UK, Blackwell, 2011
4. Vandenberg JI, Perry MD, Perrin MJ, et al: hERG K (+) channels: structure, function, and clinical significance. Physiol Rev 2012;92:1393-1478
5. Correll CU: From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010;25(suppl 2):S12-S21
6. Stroup TS, McEvoy JP, Swartz MS, et al: The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003;29:15-31
7. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
8. Huffaker SJ, Chen J, Nicodemus KK, et al: Aprimate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization, and risk of schizophrenia. Nat Med 2009;15:509-518
9. Apud JA, Zhang F, Decot H, et al: Genetic variation in KCNH2 associated with expression in the brain of a unique hERG isoform modulates treatment response in patients with schizophrenia. Am J Psychiatry 2012;169:725-734
10. Ravyn D, Ravyn V, Lowney R, et al: CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence. Schizophr Res 2013;149:1-14
11. Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J, et al: CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment. Pharmacogenet Genomics 2013;23:627-630
12. Feng Y, Pollock BG, Coley K, et al: Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol 2008;66:629-639
13. Heide J, Mann SA, Vandenberg JI: The schizophrenia-associated Kv11.1-3.1 isoform results in reduced current accumulation during repetitive brief depolarizations. PLoS One 2012;7:e45624
14. Bigos KL, Bies RR, Pollock BG, et al: Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. Mol Psychiatry 2011;16:620-625
15. Bigos KL, Pollock BG, Coley KC, et al: Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 2008;48:157-165
16. Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-989
17. Yao JA, Du X, Lu D, et al: Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature. J Pharmacol Toxicol Methods 2005;52:146-153
18. Klein TE, Altman RB, Eriksson N, et al: Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360:753-764
19. Lawler CP, Prioleau C, Lewis MM, et al: Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999;20:612-627
20. Bymaster FP, Calligaro DO, Falcone JF, et al: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96
21. Burris KD, Molski TF, Xu C, et al: Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381-389
22. 2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic reviewand pooled analysis. J Clin Psychopharmacol 2011;31:318-325
23. Uchida H, Mamo DC, Pollock BG, et al: Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study. Ther Drug Monit 2012;34:182-187
24. Olesen OV, Licht RW, Thomsen E, et al: Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit 1998;20:380-384
25. Aravagiri M, Marder SR: Brain, plasma, and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. Psychopharmacology (Berl) 2002;159:424-431
26. Glassman AH, Bigger JT Jr: Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158:1774-1782
27. Ray WA, Chung CP, Murray KT, et al: Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225-235